Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change

Nicole DeFeudis

Editor

After a post-marketing trial for Pfizer’s Xeljanz turned up concerning safety results at the beginning of the year, thwarting the whole JAK class, the FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Some FDA medical device staff reinstated just days after receiving pink slips

How AI can address ongoing challenges in the life sciences industry

Amid safe­ty con­cerns, FDA grants two new JAK ap­provals — but with added warn­ings and a key la­bel change

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Amid safety concerns, FDA grants two new JAK approvals — but with added warnings and a key label change